Posted by Michael Wonder on 03 May 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic
1 May 2026 - Apotex today announced that Health Canada has approved Apo‑Semaglutide Injection, a generic equivalent of Ozempic (semaglutide injection).
As the first Canadian‑based pharmaceutical company to gain authorisation for a generic equivalent of Ozempic, this approval reinforces Apotex's leadership in bringing high‑quality, affordable alternatives to Canadians and reflects the Company's long‑standing commitment to strengthening access to essential medicines across the country.
